Akebia Therapeutics, Inc. License Agreements
7 Contracts & Agreements
- Amendment #1 to Second Amended and Restated License Agreement, dated May 3, 2024, by and between the Company and Vifor (International) Ltd (Filed With SEC on August 8, 2024)
- License Agreement, dated May 24, 2023, by and between the Company and MEDICE Arzneimittel Ptter GmbH & Co. KG (Filed With SEC on August 28, 2023)
- License Agreement, dated December 22, 2022, by and among Akebia Therapeutics, Inc., Keryx Biopharmaceuticals, Inc. and Averoa SAS (Filed With SEC on March 10, 2023)
- Second Amended and Restated License Agreement, dated (Filed With SEC on March 1, 2022)
- Amended and Restated License Agreement, dated as of April 8, 2019, by and between Akebia Therapeutics, Inc. and Vifor (International) Ltd (Filed With SEC on August 8, 2019)
- Second Amended and Restated License Agreement, dated as of April 17, 2019, by and between Akebia Therapeutics, Inc. and Panion & BF Biotech, Inc (Filed With SEC on August 8, 2019)
- CONFIDENTIAL RESEARCH AND LICENSE AGREEMENT between AKEBIA THERAPEUTICS, INC. and Janssen Pharmaceutica NV Dated as of February 9, 2017 (Filed With SEC on May 9, 2017)
